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Abstract
Deranged calcium-phosphate metabolism contributes to the burden of morbidity and mortality in dialysis patients. This
study aimed to assess the association of the phosphaturic hormone fibroblast growth factor 23 (FGF23) and soluble Klotho
with all-cause mortality. We measured soluble Klotho and FGF23 levels at enrolment and two weeks later in 239 prevalent
hemodialysis patients. The primary hypothesis was that low Klotho and high FGF23 are associated with increased mortality.
The association between Klotho and atrial fibrillation (AF) at baseline was explored as secondary outcome. AF was defined
as presence of paroxysmal, persistent or permanent AF. During a median follow-up of 924 days, 59 (25%) patients died from
any cause. Lower Klotho levels were not associated with mortality in a multivariable adjusted analysis when examined either
on a continuous scale (HR 1.25 per SD increase, 95% CI 0.84–1.86) or in tertiles, with tertile 1 as the reference category (HR
for tertile two 0.65, 95% CI 0.26–1.64; HR for tertile three 2.18, 95% CI 0.91–2.23). Higher Klotho levels were associated with
the absence of AF in a muItivariable logistic regression analysis (OR 0.66 per SD increase, 95% CI 0.41–1.00). Higher FGF23
levels were associated with mortality risk in a multivariable adjusted analysis when examined either on a continuous scale
(HR 1.45 per SD increase, 95% CI 1.05–1.99) or in tertiles, with the tertile 1 as the reference category (HR for tertile two 1.63,
95% CI 0.64–4.14; HR for tertile three 3.91, 95% CI 1.28–12.20). FGF23 but not Klotho levels are associated with mortality in
hemodialysis patients. Klotho may be protective against AF.
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Introduction
Cardiovascular mortality in hemodialysis patients is 55% higher
than in patients with normal kidney function [1]. Vascular
calcification has been linked to deranged calcium-phosphate
metabolism. Fibroblast growth factor 23 (FGF23) regulates
phosphate metabolism by inhibiting renal phosphate reabsorption
[2,3].
The transmembrane form of Klotho functions as co-receptor of
FGF23 increasing the affinity of FGF23 to the FGF-receptor.
Klotho is a 130-kDa single-pass transmembrane protein that is
mainly expressed in the kidney [4]. The extracellular Klotho
domain is cleaved into the circulation [5]. Klotho protects against
arterial calcification [6] reduces arterial stiffness in chronic kidney
disease (CKD) [7], increases endothelial survival [8]. Klotho
expression decreases early in the course of CKD [9,10] possibly
causing FGF23 resistance [11].
High FGF23 levels were associated with an increased all-cause
mortality in hemodialysis patients [12], increased risk for end stage
renal disease (ESRD), cardiovascular events and mortality in CKD
patients [13,14]. An excess of FGF23 in CKD may be caused by
low Klotho levels triggering FGFR’s peripheral resistance to
FGF23 and thus linking FGF23-associated mortality to Klotho. To
test this hypothesis, we assessed the association of soluble Klotho
(sKlotho) with all-cause mortality as the primary outcome in a
large cohort of hemodialysis patients.
Atrial fibrillation (AF) is one of the important cardiac
comorbidities in hemodialysis patients. High FGF23 levels were
associated with AF in a recent study [15]. Little is known of the
association between low Klotho levels and AF. Experimental data
demonstrated that sKlotho is important for the function of ion
channels by regulating their cell-surface abundance through
enzymatic activation [16–18]. This can influence the peacemaker
activity of the channels in the sinoatrial node. Klotho’s expression
in the sinoatrial node has been demonstrated in animal studies,
PLOS ONE | www.plosone.org 1 July 2014 | Volume 9 | Issue 7 | e100688
Klotho-deficient animals develop sinoatrial dysfunction under
stress conditions [19]. Thus, we tested a possible association
between low Klotho level and AF.
Subjects and Methods
This study was approved by the ethics committee of medical
faculty Eberhard-Karls-university Tu¨bingen (project 191/
2009BO2). All study participants provided a written informed
consent, both for taking of blood samples and for their clinical
records to be used in the study. The research was done in
accordance with the Helsinki declaration.
Patients and control group
The study population consists of 239 prevalent maintenance
hemodialysis patients from four dialysis centers in Southwest
Germany participating in a prospective multicenter study. All the
patients received bicarbonate hemodialysis. This cohort was
established between September 2009 and September 2012 and
investigate the associations between novel biochemical risk
parameters and all-cause mortality [20,21].
Patients were eligible if they had given written informed
consent, initiation of hemodialysis was more than three months
previously and there was no evidence of acute life-threatening
illness, cardiac event, cardiac amyloidosis or cardiac procedure
within the previous two months. Clinical data were collected at
baseline from the patients’ medical records. The follow-up was
complete in all patients.
Endpoint evaluation
We defined all-cause mortality as the primary endpoint. The
primary exposure variables were plasma Klotho and FGF23 levels,
measured at study enrolment. Mortality was prospectively
recorded and coded. The follow-up was conducted by the primary
physicians of the cohort. Patients received status ‘‘survived’’ if they
continued attending their regular thrice-weekly hemodialysis
facility on 31.08.2012. No patient recovered kidney function. To
ascertain the survival status of 18 patients who moved to another
dialysis center, the new responsible primary physician was
contacted. The follow-up of 14 transplanted patients was censored
at the transplantation date.
The association between sKlotho and the prevalence of AF at
baseline was explored as a secondary outcome in a cross-sectional
manner. The diagnosis of AF was extracted from patient records.
In this cohort, 12-lead ECGs were routinely performed every 6
months and additionally if patients complained of palpitations or
chestpain. If no AF was seen on the 12-lead ECG, a 24-hour ECG
was recorded promptly. AF was defined as the presence of
paroxysmal, persistent or permanent AF.
Control group
The Klotho control group consisted of 80 healthy blood donors
who permitted use of their samples for research purposes (age
45613 years). Blinded to Klotho, we generated age-adjusted
groups by excluding hemodialysis patients older than 70 and
controls younger than 50 years. The age-adjusted groups included
109 hemodialysis patients aged 56611 and 32 controls aged 5664
years.
The FGF23 control group consisted of 55 healthy blood donors
who permitted use of their samples for research purposes. Blinded
to FGF23, we generated age-adjusted groups by including all
dialysis patients in the cohort and controls older than 60 years.
The age-adjusted groups included 239 hemodialysis patients aged
68614 and 19 controls aged 6968 years.
Laboratory assays
Blood was drawn prior to the dialysis session at enrolment and
two weeks later, collected in EDTA, cooled to 4uC, centrifuged
within 4 hours, the plasma samples were stored at 280uC for
further batched analysis. Klotho and FGF23 levels were measured
in a blinded fashion.
Human soluble a-Klotho levels were measured by Enzyme
Linked Immunosorbent Assay (ELISA) (Immuno-Biologic Labo-
ratories Co., Ltd. Japan). This novel method detects sKlotho using
a monoclonal antibody with high affinity to the human a-Klotho
protein. According to the manufacturer’s manual, the intra assay
variation coefficients (VC) are 2.7% and 3.1% at 757 pg/ml and
2969 pg/ml, the interassay VC are 6.5% and 2.9% at 706 pg/mL
and 2903 pg/mL, respectively; the analytic sensitivity is $
6.15 pg/mL. Plasma FGF23 concentrations were measured using
the two-site second generation Human FGF23 (C-Term) ELISA
Kit (Immutopics, San Clemente, CA) with mean intra-assay VC,
3%, as specified by the manufacturer. We additionally measured
FGF23 levels in 36 patients using Millipore human FGF23 (intact)
ELISA Kit (Billerica, MA, USA) and in 32 patients using Kainos
(Tokyo, Japan) murine FGF23 (intact) ELISA Kit. To verify the
capability of the chosen FGF23 and Klotho assays, we performed
dilution experiments in 11 random samples. We tested sample:
diluent ratios 1:2 and 1:4. The correlation between measured and
expected Klotho and FGF23 levels in the diluted samples was very
high: R= 0.97, P.0.001 for Klotho and R=0.99, P,0.001 for
FGF23 (Figure S1 in File S1).
Due to low sample volume in some patients, we first measured
FGF23 as it required a lower sample volume, then measuring
Klotho if enough volume remained.
Laboratory values of PTH, hemoglobin, albumin, C-reactive
protein (CRP), calcium, phosphate and alkaline phosphatase were
extracted from the patient medical records and averaged from the
available values of the previous year (4–12 values). 25(OH)vitamin
D levels were measured between 3 months before and 3 months
after study enrolment and were available in 223 patients Body
Mass Index (BMI) was calculated as postdialytic dry weight at
study enrolment in kilograms divided by the square of the height in
meters.
Clinical data
All clinical evaluation of the patients was performed at the time
the prospective cohort was established. Data on residual diuresis
(measured by 24 h urine collection and quantified in milliliters per
day), single pool Kt/V (mean of the last 4 values), interdialytic
weight gain, predialytic blood pressure (means from the last 12
values), dialysis access and membrane, time on dialysis, blood
pump, arterio-venous fistula flow (measured with a Transonic
system, Ithaca, NY, USA), presence of pulmonary hypertension
(using echocardiography or right heart catheter as indicated) were
extracted from the medical records. Transthoracic echocardiog-
raphy (TTE) was performed as clinically indicated. The results of
TTE performed within one year before and one year after the
study enrolment were extracted from the medical records and
analysed for the presence of left ventricular hypertrophy (LVH)
and left atrium dilation (LAD). These results were available in166
patients for LVH and in 177 for LAD.
Statistical analysis
We used descriptive statistics to compare baseline characteristics
and laboratory parameters according to the baseline Klotho
tertiles. Categorical variables were expressed as proportions,
continuous variables as means with standard deviations and
medians with interquartile ranges [IQR]. Normal distribution was
Klotho and Mortality in Hemodialysis Patients
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assessed by Kolmogorov-Smirnov-Test. Comparisons of groups
were made using one-way analysis of variance (ANOVA) for
continuous and the chi-squared test for categorical variables.
Kaplan-Meier analysis was performed and log-rank test of
survival distributions equality for the Klotho and FGF23 tertiles
was calculated.
Cox regression analysis was used to examine the mortality risk
associated with baseline Klotho and FGF23 levels. Similarly to
previous studies examining FGF23 and mortality risk in CKD
[13,14] and hemodialysis [12], multivariable models were applied
to adjust for potential confounders, using prior knowledge of
variables that have been associated with mortality risk in patients
undergoing hemodialysis in previous studies. We hierarchically
adjusted for demographics (age, gender, dialysis center) in model
1, dialysis-specific risk factors and comorbid conditions (dialysis
vintage, blood pressure, BMI, vascular access at study enrolment,
diabetes mellitus, coronary and valvular heart disease, AF, ICD
carriage, peripheral and cerebrovascular disease, COPD, malig-
nancy, cause of renal failure, medication and pooled Kt/V) in
model 2, and mineral metabolism levels (PTH, 25(OH)vitamin D,
phosphate and calcium), albumin, hemoglobin, CRP, cholesterol
in model 3.
We used logistic regression analysis to explore the association
between baseline Klotho levels and AF. Multivariable models were
applied to adjust for potential confounders, using variables that
have been associated with AF in previous studies. We hierarchi-
cally adjusted for demographics (age, gender, dialysis center) in
model 1, cardiovascular comorbidities (diabetes mellitus, coronary
artery and valvular heart disease, peripheral artery and cerebro-
vascular disease), anuria in model 2, and mineral metabolism
levels (FGF23, PTH, phosphate, calcium), calcium dialysate,
potassium serum and dialysate, albumin, hemoglobin, CRP,
cholesterol, thyroid stimulating hormone in model 3. Regression
analysis for Klotho tertiles at baseline with the absence of AF as
dependent variable was performed using the same models.
The statistical analyses were performed using the SPSS/PC
(version 19.0; SPSS Inc., Chicago, IL, USA) software package.
Numbers at risk were calculated using SAS 9.3 (SAS Institute,
Cary, NC, USA). All statistical tests were two-sided, and P values
,0.05 were considered significant.
Results
Baseline characteristics and outcome
From a total of 250 eligible patients, 239 (96%) were enrolled in
our study. The exclusion reasons were: six declined to participate,
two died within two weeks after enrolment, two suffered from
cardiac amyloidosis and one had initiated hemodialysis less than
three months before. The follow-up was complete in all patients.
Fifty-nine patients (25%) died within the median follow-up period
of 924 [735–996] days.
Klotho at enrolment was measured in 55 (93%) non-survivors
and 172 (96%) survivors, FGF23 in 57 (97%) non-survivors and
177 (98%) survivors. Both, Klotho and FGF23 levels at baseline
were measured in 226 (95%) patients. The baseline characteristics
and laboratory results for the full cohort and according to the
Klotho level tertiles are given in Table 1.
All-cause mortality
Median Klotho levels were similar in non-survivors and
survivors (351 [264–454] vs 338 [255–420] pg/ml, P= 0.85).
Median FGF23 levels tended to be higher in non-survivors than in
survivors (394 [111–1147] vs 201 [83–707] RU/ml, P = 0.07).
In Cox regression analysis, higher Klotho levels were not
associated with mortality in crude model and after multiple
adjustments when examined either on a continuous scale or in
tertiles, with tertile 1 as the reference category. In contrast, higher
FGF23 levels were associated with mortality after the same
adjustments (Table 2). Similar results were obtained analysing the
second blood sample (Table S1 in File S1).
Following adjustment for demographics and markers of bone
metabolism, haemoglobin, albumin and cholesterol, Klotho
remained not associated with mortality (HR 1.21 per SD increase,
95% CI 0.87–1.68, P= 0.25), in contrast to FGF23 (HR 1.56 per
SD increase, 95% CI 1.21–2.01, P = 0.001).
Cumulative survival among the three groups, stratified accord-
ing to the baseline Klotho tertiles, was similar in a Kaplan-Meier
analysis (P = 0.42) (Figure 1). For FGF23, the poorest cumulative
survival was observed among patients with levels within the top
tertile, with a log-rank test approaching significance (P= 0.05)
(Figure 2).
There was no correlation between FGF23 and Klotho levels
(R=20.03, P = 0.64).
The ratio between FGF23 (RU/ml) per SD increase and Klotho
(pg/ml) per SD increase did not substantially improve the
association with mortality (HR 1.59 95% CI 1.16–2.19,
P= 0.004) compared to FGF23 per SD increase alone in a crude
Cox regression model.
Atrial fibrillation
In 54 (23%) of 239 patients, AF had been diagnosed. The
baseline characteristics and laboratory results according to
presence or absence of AF are presented in Table S2 in File S1.
Both low Klotho and high FGF23 levels were associated with
AF (Figure 3). In logistic regression analysis, low Klotho levels
remained associated with AF in crude model, in model 1, model 2,
this association was slightly attenuated in model 3 (Table 3).
This association was similar if we adjusted only for demograph-
ics and markers of bone metabolism, haemoglobin, albumin and
cholesterol (HR 0.66 per SD increase, 95% CI 0.43–1.00,
P= 0.05).
Patients with Klotho levels within the third tertile were more
frequently free of AF (Table 4). This effect remained significant
after multiple adjustments. A similar association was observed
analysing the results of the second blood sample (Tables S3 and S4
in File S1).
The presence of AF tended to be associated with mortality in a
crude Cox regression model (HR 1.67; 95%CI 0.97–2.89;
P= 0.07).
Klotho and FGF23 levels in control group versus
hemodialysis patients
The median Klotho level in controls was higher than in
hemodialysis patients before (Figure 4A) and after age adjustment
(647 [381–974], versus 344 [116–752] pg/ml, P,0.001). Klotho
levels correlated with age in controls (R2 =20.293, P = 0.008) but
not in haemodialysis patients (P = 0.78).
The mean FGF23 level in controls was lower than in
haemodialysis patients before (Figure 4B) and after age adjustment
(93625, versus 88361940 RU/ml, P= 0.001). FGF23 levels did
not correlate with age in controls (P = 0.11) and in hemodialysis
patients (P = 0.17).
FGF23 levels measured with different kits
The mean FGF23 level measured using the Millipore assay was
102862119 pg/ml, using Immutopics assay in the same samples
Klotho and Mortality in Hemodialysis Patients
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Table 1. Baseline characteristics and laboratory parameters according to Klotho tertiles.
Full Cohort Klotho Tertile 1 Klotho Tertile 2 Klotho Tertile 3 P value
339 [260–427]
N=239 (,286 pg/ml) N=75
(286–392 pg/ml)
N=75
(.392 pg/ml)
N=77
Age (yr) 68614 67615 69612 66615 0.42
Male gender n (%) 153 (64) 55 (73) 41 (55) 49 (64) 0.06
Body-mass index* 26 [23–30] 27 [24–30] 26 [23–29] 26 [22–30] 0.41
Blood pressure (mmHg)
Systolic 134 [122–144] 137 [128–147] 134 [124–144] 127 [117–140] 0.005
Diastolic 69 [63–74] 69 [63–76] 68 [64–74] 69 [61–73] 0.55
Cause of renal failure n (%)
Diabetes mellitus 63 (26) 24 (36) 19 (25) 18 (23) 0.48
Hypertension 19 (8) 5 (7) 8 (11) 3 (4) 0.26
Glomerulonephritis 71 (30) 24 (32) 23 (31) 22 (29) 0.90
PKD 11 (5) 2 (3) 5 (7) 4 (5) 0.51
Others/unknown 75 (31) 20 (27) 20 (27) 30 (39) 0.17
Cardiac comorbidities n (%)
Coronary artery disease 73 (31) 24 (32) 24 (32) 19 (25) 0.52
PCI/CABG 45 (19) 16 (21) 19 (25) 17 (22) 0.78
Valvular heart disease 61 (26) 13 (17) 20 (27) 22 (29) 0.27
Atrial fibrillation 54 (23) 19 (25) 20 (27) 10 (13) 0.08
ICD implantation 4 (2) 1 (1) 0 (0) 2 (3) 0.37
LVH{ 101 (61) 36 (62) 34 (62) 28 (52) 0.18
Pulmonary hypertension 16 (7) 3 (4) 6 (8) 5 (6) 0.59
Other comorbidities n (%)
Diabetes mellitus 90 (38) 29 (39) 24 (32) 32 (43) 0.46
PVD 80 (33) 28 (37) 23 (31) 23 (31) 0.56
Stroke 38 (16) 8 (11) 18 (24) 9 (12) 0.04
Vasculitis 8 (3) 3 (4) 2 (3) 2 (3) 0.85
Malignoma 34 (14) 14 (19) 7 (9) 11 (14) 0.26
COPD 19 (8) 3 (4) 8 (11) 7 (9) 0.29
Dialysis vintage (months) 59653 49640 67656 62660 0.10
Duration of dialysis session (hours) 4.260.4 4.360.5 4.160.3 4.260.42 0.24
Dialysis access at baseline n (%)
Arteriovenous fistula 169 (71) 49 (65) 54 (72) 56 (73) 0.51
PTFE graft 31 (13) 11 (15) 7 (9) 11 (14) 0.57
Tunnelled catheter 38 (16) 15 (20) 13 (17) 10 (13) 0.50
Dialysis membrane n (%)
High-flux 228 (95) 73 (97) 70 (93) 73 (95) 0.51
Low-flux 11 (5) 2 (3) 5 (7) 4 (5)
Dialysis modality
Hemodiafiltration 54 (23) 18 17 15 0.79
Hemodialysis only 185 (77) 57 58 62
Anuric patients n (%) 93 (39) 28 (37) 30 (40) 32 (42) 0.86
Residual diuresis (ml/24 hours) 250 [0–1005] 300 [0–1100] 200 [0–1025] 200 [0–900] 0.75
Interdialytic weight gain (kg) 1.9 [1.3–2.5] 1.9 [1.4–2.7] 1.82 [1.22–2.43] 1.86 [1.17–2.48] 0.52
Shunt flow (ml/min) 11776638 10996512 12876670 11606694 0.28
Singe pool Kt/V 1.6 [1.4–1.7] 1.52 [1.33–1.65] 1.60 [1.40–1.77] 1.53 [1.39–1.71] 0.24
Ca, dialysate 1.460.2 1.460.2 1.460.2 1.460.2 0.98
K, dialysate 2.460.6 2.360.6 2.360.6 2.560.6 0.40
FGF23 (RU/ml) 88361940 111762866 60961025 76161370 0.25
PTH (pg/ml) 2496177 2826184 2406188 2346152 0.20
Klotho and Mortality in Hemodialysis Patients
PLOS ONE | www.plosone.org 4 July 2014 | Volume 9 | Issue 7 | e100688
100161627 RU/ml. The mean FGF23 level measured using
Kainos assay was 69061001 pg/ml, using the Immutopics assay
in the same samples 72361279 RU/ml.
FGF23 levels measured using the Immunotopic assay correlated
with the levels measured using the Millipore (R= 0.73, P,0.001)
and Kainos assay (R= 0.66, P,0.001). FGF23 levels measured
using Millipore assay correlated with the levels measured using
Kainos assay (R= 0.97, P,0.001).
Discussion
In this cohort of ESRD patients with long-term follow-up, we
report three major findings. First, FGF23 but not Klotho levels
were predictive for all-cause mortality. This association remained
significant after multivariate adjustments and was confirmed
analysing the results of the second blood sample drawn two weeks
after study enrolment. Second, high Klotho levels may exert a
protective effect against AF. Interestingly, Klotho was more
strongly associated with AF than the presence of traditional
cardiovascular risk factors such as complete loss of kidney function,
age, gender, arteriosclerosis and valvular heart disease. Even the
fully adjusted model, additionally including levels of other mineral
metabolites known as risk factors for structural heart disease,
approached statistical significance. Third, Klotho levels in healthy
controls were higher than in hemodialysis patients.
Assays for Klotho have been lacking until now, and data on the
regulatory mechanism, function and expression of Klotho has
been scant. Only very recently, a sandwich enzyme-linked
immunosorbent assay (ELISA) has been developed for the soluble
form of Klotho [22]. Using this, we determined Klotho and
FGF23 blood levels in a large multicentre cohort of hemodialysis
patients and tested the hypothesis that low blood Klotho levels
could be associated with all-cause mortality. To our knowledge,
this is the first study exploring an association of Klotho with all-
cause mortality in hemodialysis patients.
Although Klotho has been shown to exert direct vasculopro-
tective effects, our data extend recent observations by Seiler et al in
patients with stage 2–4 chronic kidney disease which showed
Klotho levels not to be associated with mortality. As Seiler and
authors excluded ESRD patients, the need for a study with ESRD-
patients has been highlighted [23].
Moreover, recent experimental and clinical studies have
challenged previous views on Klotho. Anour et al. failed to prove
a physiological role for soluble and transmembrane Klotho in
mineral metabolism and glucose homeostasis [24]. A study by
Komaba et al. found no association between Klotho and the major
players in arterial calcification in CKD-related mineral bone
disorder PTH and FGF23 [25]. Furthermore, calcimimetic
therapy in a hemodialysis patients was followed by very modest
effects on Klotho levels, raising the question of whether these
effects are biologically meaningful [25]. Levels of Klotho did not
appear to correlate with residual renal function in a prevalent
cohort of peritoneal dialysis patients [26], findings that were also
seen in our cohort. No association between Klotho gene variants
and the presence of valvular or vascular calcification was observed
in the Framingham Offspring Cohort [27]. Taken together, the
current data allow the conclusion that soluble Klotho levels do not
reflect clinical outcome in patients with CKD.
FGF23 rather than Klotho more appropriately reflects cardio-
vascular risk. FGF23 is the earliest marker of deranged phosphate
Table 1. Cont.
Full Cohort Klotho Tertile 1 Klotho Tertile 2 Klotho Tertile 3 P value
339 [260–427]
N=239 (,286 pg/ml) N=75
(286–392 pg/ml)
N=75
(.392 pg/ml)
N=77
25(OH)vitamin D (ng/ml) 28 [21–35] 28 [20–35] 27 [21–34] 29 [20–36] 0.52
Phosphate (mmol/l) 1.6 [1.4–1.9] 1.6 [1.3–1.9] 1.6 [1.3–1.8] 1.6 [1.4–1.9] 0.70
Ca, serum (mmol/l) 2.3 [2.2–2.4] 2.3 [2.2–2.4] 2.3 [2.2–2.4] 2.3 [2.2–2.4] 0.40
AP (U/l) 91642 85641 91643 97645 0.14
K, serum (mmol/l) 5.060.6 5.160.6 5.160.6 5.060.6 0.37
Albumin (g/l) 3764 3765 3764 3764 0.82
Hemoglobin (g/dL) 11.5 [11.1–12.0] 11.5 [11.2–11.8] 11.6 [11.2–12.0] 11.5 [11.2–12.0] 0.9
C-reactive protein (mg/l) 12612 13614 12611 12611 0.80
Cholsterol (mg/dl) 167 [141–196] 171 [147–200] 172 [143–199] 156 [141–193] 0.52
Medication use n (%)
Phosphate binders 205 (86) 64 (85) 64 (85) 67 (87) 0.88
Vitamin d replacement 233 (97) 72 (96) 74 (99) 75 (97) 0.76
ACE-I or ARB 126 (53) 48 (64) 39 (52) 33 (43) 0.04
b-Blockers 153 (64) 56 (75) 45 (60) 42 (55) 0.03
Statin 101 (42) 41 (55) 28 (37) 26 (34) 0.02
Plus-minus values are means 6 SD. Numbers with ranges in square brackets are medians and interquartile ranges. P values are for the comparisons between the three
Klotho tertiles. To convert the values for calcium to milligrams per deciliter, multiply by 4.000. To convert the values for phosphate to milligrams per deciliter, multiply
by 3.0969.
*The body-mass index is the weight in kilograms divided by the square of the height in meters.
{Based on 166 available clinically indicated transthoracic echocardiography results.
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitors; AF, atrial fibrillation; AP, alkaline phosphatase; ARB, angiotensin receptor blocker; COPD, chronic
obstructive pulmonary disease; FGF23, fibroblast growth factor 23; ICD, implantable cardioverter defibrillator; IQR, interquartile range; PTFE, Polytetrafluorethylen; PTH,
parathyroid hormone; PKD, polycystic kidney disease; PVD Peripheral vascular disease; T, Tertile; U, unit.
doi:10.1371/journal.pone.0100688.t001
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metabolism, increasing before PTH and phosphate levels and
before vitamin D levels decrease [14]. Studies found FGF23 to be
independently associated with mortality in hemodialysis patients
[12], with ESRD development, cardiovascular events and
mortality in CKD patients [13,14]. In accordance with those
previous studies, our study highlighted FGF23 as a valuable
biomarker for assessment of cardiovascular risk in hemodialysis
patients.
The FGF23 levels in this cohort appear lower compared to
previous studies measuring C-terminal FGF23 in hemodialysis
patients [12]. The cause is not completely clear. First, despite a
good recovery in the dilution experiments using our samples, we
cannot exclude some assay differences. Second, as FGF23
increases in the circulation with increasing phosphate load and
vice versa [28], a further contributor could be differences in
phosphate load. In our cohort, we may have had a high
phosphate-clearance due to relatively long dialysis duration [29],
a high percentages of high-flux dialysis membrane and hemodia-
filtration (HDF) usage. All three modalities enhance phosphate
clearance and possibly FGF23 removal itself. Previous studies
showed that more intensive dialysis treatment can substantially
lower FGF23 levels. Zaritzky et al achieved a median of 823 RU/
ml in daily hemodialysis versus 2521 RU/ml in conventional
hemodialysis patients [30]. Using HDF, Patrier et al achieved a
20% higher FGF23 clearance over high-flux hemodialysis only.
Hemodialysis studies with FGF23 mostly do not give the exact
information about dialysis treatment details hindering a direct
comparison between studies. Importantly, although the FGF23
levels are lower in this study, its association with mortality is in
accordance with previous work [12,14].
Interestingly, the analytical concordance between Kainos and
Millipore assays was in much closer agreement than between each
of them and the Immutopics assay. A similar lack of agreement
was found by Smith et al in a smaller group of hemodialysis
patients [31]. The authors suggest that this might be due to
differences in calibration. As the sample number where FGF23
levels were determined using different assays was not high in our
study, further studies are warranted and careful interpretation of
our results is recommended. Harmonisation of available assays
would facilitate interpretation of studies where different assays are
used.
Of note, patients with AF had lower Klotho levels than patients
without AF. This effect remained significant even after the
adjustment for cardiovascular comorbidities and approached
significance in the fully adjusted model. Thus, high Klotho levels
seem to exert a protective effect against AF. The absolute
differences in Klotho levels between the patients groups with
and without AF was small albeit significant. Small differences in
sKlotho levels may be physiologically relevant. Relatively small
increases in sKlotho levels were for example shown to induce overt
changes in vascular tone of animal and human blood vessels in an
experimental study by Six et al [32]. These dose dependent effects
were shown to be due to sKlotho mediated intracellular reactive
oxygen species (ROS) and nitric oxide (NO) production. We found
no studies examining dose-dependent influence of ion channels by
sKlotho. The physiological relevance of this relatively small
difference in our study needs to be confirmed by further studies
and must be regarded as a pilot hypothesis.
Concomitantly, patients with AF had higher FGF23 levels than
patients without AF. The latter finding is in agreement with data
from Seiler et al who found higher FGF23 levels in patients with
AF in 885 subjects with normal and reduced kidney function
undergoing elective coronary angiography [15].
A mechanistic explanation for the sinoatrial dysfunction might
be arteriosclerotic changes caused by Klotho deficiency. But an
even more plausible hypothesis is that Klotho might be essential
for the function of ion channels which are responsible for the
peacemaking activity in the sinoatrial node. In fact, a study by
Figure 1. Cumulative survival by tertiles of secreted Klotho.
Patients were stratified by their baseline Klotho levels according to the
tertiles. Kaplan-Meier analysis with long-rank test did not reveal a
significant difference between groups (P = 0.42).
doi:10.1371/journal.pone.0100688.g001
Figure 2. Cumulative survival by tertiles of Fibroblast growth
factor 23 (FGF23). Patients were stratified by their FGF23 levels
according to the tertiles. Kaplan-Meier analysis with long-rank test
approached a significant difference between groups (P = 0.05).
doi:10.1371/journal.pone.0100688.g002
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Takeshita et al. demonstrated specific expression of Klotho in the
sinoatrial node peacemaker cells [19]. Furthermore, electrophys-
iological studies revealed significant sinus node dysfunction in
Klotho knock-out mice [19]. Recent experimental research
demonstrates that sKlotho can regulate the cell-surface abundance
of ion channels such as Ca2+ and K+ channels [16]. The
stimulation of the Ca2+ channel TRPV5, promoting the renal
Ca2+ reabsorption by sKlotho was demonstrated in an animal
study by Alexander et al [33]. Klotho has been shown to exhibit
cardioprotective effects by downregulation of TRPC6 channels in
the heart. But, these studies were performed only on isolated
cardiac myocytes using supraphysiologic soluble Klotho concen-
trations. [17,18,34]. Low Klotho levels may therefore have led to
sinoatrial dysfunction secondary to disturbed ion channels
regulation in the cardiac peacemaker cells. Through protecting
against AF, which is mostly attributed to senescence processes,
Klotho appears to have anti-aging properties. With decreasing
Klotho tertiles and therefore increasing AF prevalance, the
treating physicians prescribed beta-, renin-angiotensin-aldos-
teron-blockers and statins more frequently (Table 1).
Klotho mainly derives from the renal tubular cells [4] both
declining early in the CKD course [9,35]. Correspondingly,
Klotho levels in our healthy control group were higher than in
CKD patients in the Study by Seiler et al [23] and the latter higher
than in our hemodialysis patients (respective medians 690, 538 and
349 pg/ml). All levels measured using the same assay. But, Klotho
levels were neither associated with CKD stages 2–4 [23] nor with
residual kidney function in our patients. A possible explanation
could be a reduced renal clearance in CKD. The fact that Klotho
levels are maintained even with complete loss of kidney function
suggests that sKlotho may be important for physiologic functions
such as ion channels. The lack of association with mortality
remains to be elucidated. One possibility is that Klotho level does
not reflect membrane-bound Klotho function, the latter only being
measurable by invasive methods.
Several limitations merit consideration. Firstly, the study was
not designed to establish the exact cause of death. This limitation
is common and may partly be due to the relatively low autopsy
rate [14]. Due to this, we defined all-cause mortality rather than
myocardial infarction (MI) as the primary end-point of the study
with the knowledge that cardiovascular disease is the main
contributor to mortality in ESRD [1]. Secondly, we did not define
non-fatal MI as an end-point. Non-fatal MI rarely occurs in
hemodialysis patients [36], the competing risk of cardiac death is
observed to be several-fold greater than that of non-fatal MI [37]
corresponding to the finding that coronary media calcifications
rather than arterial plaques have a greater impact on mortality in
dialysis patients [38,39] and are the main autopsy finding [40]. We
also did not record smoking and alcohol consumption habits at
study enrolment. Thirdly, we cannot comment on unreported,
asymptomatic or still undetected AF episodes. Furthermore, the
association between low Klotho levels and AF was analysed in a
cross-sectional manner and we have no data on AF incidence
during the observational period. Nevertheless our hypothesis is
supported, as the association between low Klotho levels and AF
remained significant during analysis of the second independent
blood sample, even after multiple adjustments. This hypothesis
needs to be confirmed by further prospective studies. Experimental
studies with systemic Klotho delivery in Klotho-deficient animals
with AF could provide valuable information for understanding the
mechanism underlying sinoatrial dysfunction and possibly lead to
new therapeutic approaches in patients with AF. Another potential
problem is that the three commercially available assays for the
Klotho measurement differ in quality, as recently demonstrated by
Heijboer et al [41]. However, we used the so far best validated
assay with the lowest within- and between-run variation among
the commercially available assays [41].
In conclusion, FGF23, but not Klotho levels, are associated with
long-term mortality in ESRD-patients.
Figure 3. Klotho and FGF23 levels in patients with and without
atrial fibrillation.
doi:10.1371/journal.pone.0100688.g003
Table 4. Regression analysis for Klotho tertiles with the absence of atrial fibrillation.
Klotho Tertile 1,
N=75 (,286 pg/ml)
Klotho Tertile 2,
N=75 (286–392 pg/ml)
Klotho Tertile 3,
N=77 (.392 pg/ml)
OR (95%CI) P value OR (95%CI) P value
Crude Reference 2.75 (1.65–4.59) ,0.001 6.70 (3.45–13.02) ,0.001
Model 1* Reference 1.09 (0.52–2.27) 0.83 2.90 (1.27–6.64) 0.01
Model 2{ Reference 1.23 (0.54–2.78) 0.63 3.71 (1.49–9.25) 0.005
Model 3` Reference 1.00 (0.40–2.59) 1.00 3.02 (1.03.89–8.82) 0.04
*Model 1: adjusted for age and gender.
{Model 2: adjusted for covariates in Model 1 plus diabetes mellitus, coronary artery disease, valvular heart disease, peripheral vascular disease, stroke and anuria.
`Model 3: adjusted for covariates in Model 2 plus parathyroid hormone, fibroblast growth factor 23, calcium, phosphate, albumin, calcium dialysate, potassium serum
and dialysate, hemoglobin C-reactive protein, cholesterol and thyroid stimulating hormone.
Abbreviations: CI, confidence interval; OR, odds ratio.
doi:10.1371/journal.pone.0100688.t004
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